Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 06:20PM GMT
Release Date Price: €55 (+2.80%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have Barry Greene, CEO of Sage with us here today. Thank you, Barry.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Thank you. Great to be here. Thanks for having the sun come out, and thanks for Goldman for having us.

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Did the sun come out?

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

(inaudible)

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. So maybe to start here. Zuranolone is up for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot